A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression

NCT Number	NCT07446049
Lead Sponsor	Convalife (Shanghai) Co., Ltd.
Conditions	Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
Enrollment	180 participants
Start Date	2026-05-01
Primary Completion	2028-01-09 (estimated)
Study Completion	2028-04-08 (estimated)
Updated on ClinicalTrials.gov	2026-03-03